A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Trial Profile

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Pelvic cancer; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-052
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 Feb 2018 Planned End Date changed from 21 Jun 2018 to 28 Sep 2018.
    • 26 Sep 2017 Results (data cut off Sept 1, 2016) published in the Lancet Oncology
    • 12 Sep 2017 Results assessing efficacy of pembrolizumab as first-line therapy in a subgroup of senior patients with cisplatin-ineligible advanced urothelial cancer, presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top